Preclinical studies on its use in HER2 epithelial ovarian carcinoma, uterine serous carcinoma, and uterine and ovarian carcinosarcomas show antitumor activity and are anticipated to be the subject of further investigation [47,48,49]. The gene discussed is ERBB2; the disease is ovarian carcinosarcoma.